Diane L. Rossi

Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in <i>BRCA1/2</i> –wild-type Triple-Negative Breast Cancer

Thomas M. Cardillo, Robert M. Sharkey, Diane L. Rossi et al. · Clinical Cancer Research · 2017 · 127 citations

Medicine, Oncology, Pharmacology +17

Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab

Edmund A. Rossi, David M. Goldenberg, Rosana Michel et al. · Blood · 2013 · 111 citations

Life Sciences, Immunology, Molecular Biology +12

Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells

Chien‐Hsing Chang, Yang Wang, Rongxiu Li et al. · Cancer Research · 2017 · 83 citations

Pharmacy, Oncology, Pharmacology +17

Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer

Thomas M. Cardillo, Diane L. Rossi, Maria Zalath et al. · Oncotarget · 2020 · 52 citations · Full text

Medicine, Oncology, Pharmacology +17

A Bispecific Antibody-IFNα2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells

Edmund A. Rossi, Diane L. Rossi, Rhona Stein et al. · Cancer Research · 2010 · 44 citations · Full text

Pharmacy, Oncology, Pharmacology +17